Incidence and time course of neutropenia in patients treated with rituximab‐based therapy for non‐malignant immune‐mediated hematologic diseases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence and time course of neutropenia in patients treated with rituximab‐based therapy for non‐malignant immune‐mediated hematologic diseases

Published:2020-02-17 Issue:5 Volume:95 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Malpica Castillo Luis E.¹^ORCID,Palmer Shannon²,Zhu Anqi³,Deal Allison M.³,Chen Sheh‐Li²,Moll Stephan¹

Affiliation:

1. Division of Hematology‐Oncology, Department of MedicineUniversity of North Carolina Chapel Hill North Carolina

2. Department of PharmacyUniversity of North Carolina Chapel Hill North Carolina

3. Biostatistics Shared Resource, Lineberger Comprehensive Cancer CenterUniversity of North Carolina Chapel Hill North Carolina

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25751

Reference6 articles.

1. Late-Onset Neutropenia After Rituximab Treatment

2. Rituximab-Related Late-Onset Neutropenia in Patients with Rheumatic Diseases: Successful Re-Challenge of the Treatment

3. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma

4. A Prospective Study to Evaluate the Efficacy, Safety and Response Duration of Newly Diagnosed Adult Immune Thrombocytopenia Patients Treated with Low Dose Rituximab and High Dose of Dexamethasone

5. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis;Internal Medicine;2024

2. Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study;Platelets;2023-04-27

3. EXPRESSIONS OF BCL10 PROTEIN AND APC IN GASTRIC MALT LYMPHOMA AND THEIR CORRELATIONS WITH CLINICOPATHOLOGICAL CHARACTERISTICS;ACTA MEDICA MEDITERR;2021

4. Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs;Hematology;2020-12-04

5. Mercaptopurine/rituximab;Reactions Weekly;2020-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3